Home›Trial›NCT06447025
🔬NCT06447025Phase 2RECRUITING

An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia

Study Summary

An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of CTI-1601 enrolling patients with FRDA who have participated in a prior clinical study of CTI-1601 as well as adolescents and adults with FRDA who have not participated in a prior clinical study of CTI-1601.

Conditions
Friedreich Ataxia
Interventions / Drugs
CTI-1601
View on ClinicalTrials.gov ↗
Sponsor
LRMR
Larimar Therapeutics
Rare Disease
D39/100
Study Details
Enrollment85 participants
Primary Completion—
Lead SponsorLarimar Therapeutics, Inc.
Data Retrieved2026-04-11 04:20:05.037888+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.